Professional
Added to YB: 2024-04-30
Pitch date: 2024-04-24
ROIV [bullish]
Roivant Sciences Ltd.
+105.01%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Market Cap
$14.1B
Pitch Price
$10.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.39
P/E
-20.20
EV/Sales
505.07
Sector
Biotechnology
Category
special_situation
Show full summary:
Tourlite Capital Portfolio Holding: Roivant Sciences Ltd.
ROIV: >50% of market cap in cash. Accretive buyback of $648M at $9.10/share. Arbutus wins 3/4 claims in hearing, supporting '378 patent. Brepocitinib Ph2 shows promise in non-infection uveitis (NIU), a >$1B opportunity. Ph3 to start 2H. Attractive opportunity.
Read full article (1 min)